| 指数 | 收盘 | | 涨跌（％） | | | --- | --- | --- | --- | --- | | 名称 | （点） | 1 日 | 5 日 | 1 月 | | 上证指数 | 4147 | 0.72 | 0.27 | 1.6 | | 深证综指 | 2746 | 1.21 | 0.01 | 2.46 | | 风格指数 (％) | 昨日 | 近 1 个月 | 近 6 个月 | | --- | --- | --- | --- | | 大盘指数 | 0.56 | 0.59 | 5.01 | | 中盘指数 | 1.39 | 0.21 | 21.94 | | 小盘指数 | 1.59 | -0.96 | 15.17 | | 涨幅居前 行业(％) | 昨日 | 近 1 个月 | 近 6 个月 | | --- | --- | --- | --- | | 小金属Ⅱ | 7.77 | 11.75 | 60.09 | | 冶钢原料 | 5.65 | 5.49 | 59.48 | | 房地产服务 | 5.41 | 7.08 | 4.44 | | 普钢Ⅱ | 5.04 | 3.31 | 3.25 | | 航天装备Ⅱ | ...

斯托克欧洲600指数收盘几无变动，此前一度上涨0.7%。化工股录得近四年来最好一天，市场看好该地 区放宽减排规则，这助推了向增长前景势将改善的公司轮动的势头。电信和必需消费品等防御性板块也 上涨。 斯托克欧洲600指数收盘几无变动，此前一度上涨0.7%。化工股录得近四年来最好一天，市场看好该地 区放宽减排规则，这助推了向增长前景势将改善的公司轮动的势头。电信和必需消费品等防御性板块也 上涨。 欧洲股市表现平淡，汽车和化工等周期性板块的上涨抵消了科技股的下跌。诺和诺德在发布令人大跌眼 镜的销售预测之后股价暴跌17%。 相比之下，科技股延续跌势，前日软件股因市场对人工智能颠覆性影响的担忧而下跌。Cellnex Telecom SA因周二晚些时候宣布新的高层管理架构而上涨，提振了所在板块。由于金属反弹势头在尾盘消退， 矿业股回吐涨幅，最终收跌。 个股方面，葛兰素史克上涨6.9%，受HIV药物和一种现已获批用于治疗肺部疾病的哮喘药物提振，该公 司报道的第四季度业绩强于预期。诺和诺德跌幅为7月以来最大，市值蒸发超过400亿美元，给医疗保健 板块带来了压力。 桑坦德走低3.5%，此前这家西班牙的银行宣布以120亿美元收购 ...

英国制药巨头葛兰素史克(GSK.US)涨超7%，最高触及57.34美元，创下历史新高。消息面上，葛兰素史 克去年总营收同比增长4%至326.7亿英镑，超过分析师预期的325亿英镑；归属于股东的净利润同比大 幅增长121.7%至57.2亿英镑，合每股收益1.388英镑。期内，专科药物销售额同比增长17%，达到134.7 亿英镑，主要得益于HIV药物需求强劲。董事会宣布派发季度股息每股0.18英镑，使得2025年全年股息 达到每股0.66英镑，高于2024年的每股0.61英镑。(格隆汇) ...

格隆汇2月4日｜英国制药巨头葛兰素史克周三发布财报显示，得益于HIV和哮喘药物的强劲表现，该公 司第四季度利润超出预期。这家英国制药商表示，剔除部分项目后的调整后每股收益为25.5便士，高于 分析师预期。公司预计今年利润增长将在7%至9%之间。此前部分分析师预测的每股收益增长指引约为 6%至8%。新任首席执行官Luke Miels 设定了一个极具潜力且有望超越的目标，而抗癌药物Blenrep的销 售额在今年也有望提振营收。 ...

Group 1 - The articles discuss the ongoing developments in land use and agricultural practices, highlighting the changes in acreage and the impact on production [1][2][3] - There is a focus on the regulatory environment affecting land use, with mentions of audits and assessments that continue to influence agricultural land management [2][4] - Projections for land use by 2025 indicate significant changes, with specific acreage targets set for various agricultural practices [1][3] Group 2 - The articles emphasize the importance of sustainable practices in agriculture, noting the need for compliance with environmental standards [2][4] - There are references to the economic implications of land use changes, including potential impacts on local economies and agricultural output [1][3] - The discussion includes the role of technology and innovation in improving agricultural efficiency and land management [2][3]

Core Viewpoint - The U.S. Secretary of Health, RFK Jr., plans to abolish the advisory committee responsible for cancer screening, which also oversees the approval recommendations for HIV medications [1] Group 1 - The advisory committee's role included overseeing cancer screening guidelines and providing recommendations for HIV drug approvals [1] - The decision to abolish the committee may impact the regulatory landscape for cancer and HIV treatments [1]

Core Viewpoint - The legal opinion letter from Shanghai Chengming Zhenzheng Law Firm confirms the validity of the cancellation of unvested restricted stock under Jiangsu Aidi Pharmaceutical Co., Ltd.'s 2022 incentive plan, stating that necessary approvals and authorizations have been obtained and that the actions comply with relevant laws and regulations [1][9]. Summary by Sections Approval and Authorization of Stock Cancellation - The company has obtained necessary approvals for the cancellation of unvested restricted stock as per the 2022 incentive plan, including resolutions from various meetings and independent directors' opinions [5][6][9]. Details of Canceled Restricted Stock - A total of 500,501.6 shares of restricted stock have been canceled due to various reasons: - 252,450 shares were canceled because 36 initial grantees and 13 reserved grantees left the company [6][9]. - 231,060 shares were canceled due to unmet performance targets in the HIV drug business for the years 2022, 2023, and 2024 [7][8][9]. - 16,650 shares were canceled as 10 reserved grantees voluntarily forfeited their rights [8][9]. - 3,416 shares were canceled because one initial grantee failed to pay the subscription fee [8][9]. Compliance with Regulations - The cancellation of restricted stock aligns with the provisions of the Company Law, Securities Law, and relevant management regulations, confirming that the actions taken are legally compliant [9].

Core Viewpoint - The company announced the cancellation of 1.504 million shares of unvested restricted stock from its 2023 stock incentive plan due to the departure of certain incentive targets and unmet performance criteria [6][7]. Group 1: Approval Process of the Stock Incentive Plan - The company held multiple board and supervisory meetings to approve the stock incentive plan and its related documents from August to September 2023 [1][2][3][4]. - Independent directors provided opinions on the incentive plan, and the supervisory board verified the relevant matters [2][4]. Group 2: Details of the Canceled Restricted Stock - A total of 126,000 shares were canceled due to three incentive targets leaving the company [6]. - The remaining shares were canceled because the company did not meet its performance targets for the fiscal years 2023 and 2024, with reported revenues of approximately 411.36 million yuan and 417.80 million yuan respectively [6]. - The HIV drug division also failed to meet its performance targets, with revenues of approximately 73.58 million yuan in 2023 and 149.90 million yuan in 2024 [6]. Group 3: Impact of the Canceled Restricted Stock - The cancellation of the restricted stock will not have a significant impact on the company's financial status or operational results, nor will it affect the stability of the management team or the ongoing implementation of the stock incentive plan [7]. Group 4: Supervisory Board and Legal Opinions - The supervisory board agreed that the cancellation of the restricted stock complies with relevant laws and regulations, and does not harm shareholder interests [7]. - Legal opinions confirmed that the cancellation aligns with the regulations governing stock incentives and necessary disclosure obligations [8].